Spectral AI, Inc.
Spectral AI, Inc. (MDAI) Stock Competitors & Peer Comparison
See (MDAI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDAI | $2.24 | -7.82% | 71.3M | -4.23 | -$0.53 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ISRG | $439.92 | +4.46% | 155.8B | 53.58 | $8.21 | N/A |
| ABT | $87.91 | +4.07% | 153.1B | 24.61 | $3.57 | +2.79% |
| SYK | $313.22 | +2.11% | 120.1B | 36.22 | $8.65 | +1.10% |
| MDT | $77.32 | +1.54% | 99.3B | 21.59 | $3.58 | +3.68% |
| BSX | $55.92 | +6.15% | 83.2B | 23.41 | $2.39 | N/A |
| BRKRP | $332.01 | +0.00% | 50.1B | N/A | N/A | +0.47% |
| EW | $82.39 | +1.25% | 47.4B | 44.53 | $1.85 | N/A |
| RMD | $204.15 | +1.12% | 29.6B | 19.67 | $10.38 | +1.17% |
Stock Comparison
MDAI vs BSX-PA Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, MDAI is priced at $2.24, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, MDAI's ROE is +1.79%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, MDAI is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BSX-PA's competition here
MDAI vs ISRG Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ISRG has a market cap of 155.8B. Regarding current trading prices, MDAI is priced at $2.24, while ISRG trades at $439.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ISRG's P/E ratio is 53.58. In terms of profitability, MDAI's ROE is +1.79%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, MDAI is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ISRG's competition here
MDAI vs ABT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ABT has a market cap of 153.1B. Regarding current trading prices, MDAI is priced at $2.24, while ABT trades at $87.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ABT's P/E ratio is 24.61. In terms of profitability, MDAI's ROE is +1.79%, compared to ABT's ROE of +0.12%. Regarding short-term risk, MDAI is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ABT's competition here
MDAI vs SYK Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SYK has a market cap of 120.1B. Regarding current trading prices, MDAI is priced at $2.24, while SYK trades at $313.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SYK's P/E ratio is 36.22. In terms of profitability, MDAI's ROE is +1.79%, compared to SYK's ROE of +0.15%. Regarding short-term risk, MDAI is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SYK's competition here
MDAI vs MDT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, MDT has a market cap of 99.3B. Regarding current trading prices, MDAI is priced at $2.24, while MDT trades at $77.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas MDT's P/E ratio is 21.59. In terms of profitability, MDAI's ROE is +1.79%, compared to MDT's ROE of +0.10%. Regarding short-term risk, MDAI is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check MDT's competition here
MDAI vs BSX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BSX has a market cap of 83.2B. Regarding current trading prices, MDAI is priced at $2.24, while BSX trades at $55.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BSX's P/E ratio is 23.41. In terms of profitability, MDAI's ROE is +1.79%, compared to BSX's ROE of +0.15%. Regarding short-term risk, MDAI is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BSX's competition here
MDAI vs BRKRP Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BRKRP has a market cap of 50.1B. Regarding current trading prices, MDAI is priced at $2.24, while BRKRP trades at $332.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BRKRP's P/E ratio is N/A. In terms of profitability, MDAI's ROE is +1.79%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, MDAI is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BRKRP's competition here
MDAI vs EW Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, EW has a market cap of 47.4B. Regarding current trading prices, MDAI is priced at $2.24, while EW trades at $82.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas EW's P/E ratio is 44.53. In terms of profitability, MDAI's ROE is +1.79%, compared to EW's ROE of +0.11%. Regarding short-term risk, MDAI is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check EW's competition here
MDAI vs RMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, RMD has a market cap of 29.6B. Regarding current trading prices, MDAI is priced at $2.24, while RMD trades at $204.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas RMD's P/E ratio is 19.67. In terms of profitability, MDAI's ROE is +1.79%, compared to RMD's ROE of +0.24%. Regarding short-term risk, MDAI is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check RMD's competition here
MDAI vs DXCM Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, DXCM has a market cap of 25.1B. Regarding current trading prices, MDAI is priced at $2.24, while DXCM trades at $65.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas DXCM's P/E ratio is 27.94. In terms of profitability, MDAI's ROE is +1.79%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, MDAI is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check DXCM's competition here
MDAI vs PHG Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PHG has a market cap of 24.8B. Regarding current trading prices, MDAI is priced at $2.24, while PHG trades at $26.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PHG's P/E ratio is 22.26. In terms of profitability, MDAI's ROE is +1.79%, compared to PHG's ROE of +0.09%. Regarding short-term risk, MDAI is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check PHG's competition here
MDAI vs STE Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, STE has a market cap of 20.9B. Regarding current trading prices, MDAI is priced at $2.24, while STE trades at $212.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas STE's P/E ratio is 26.86. In terms of profitability, MDAI's ROE is +1.79%, compared to STE's ROE of +0.11%. Regarding short-term risk, MDAI is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check STE's competition here
MDAI vs ABMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, MDAI is priced at $2.24, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ABMD's P/E ratio is 65.36. In terms of profitability, MDAI's ROE is +1.79%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, MDAI is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ABMD's competition here
MDAI vs ZBH Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ZBH has a market cap of 16.5B. Regarding current trading prices, MDAI is priced at $2.24, while ZBH trades at $85.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ZBH's P/E ratio is 22.05. In terms of profitability, MDAI's ROE is +1.79%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, MDAI is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ZBH's competition here
MDAI vs SNN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, MDAI is priced at $2.24, while SNN trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SNN's P/E ratio is 21.19. In terms of profitability, MDAI's ROE is +1.79%, compared to SNN's ROE of +0.12%. Regarding short-term risk, MDAI is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SNN's competition here
MDAI vs PEN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, MDAI is priced at $2.24, while PEN trades at $326.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PEN's P/E ratio is 75.09. In terms of profitability, MDAI's ROE is +1.79%, compared to PEN's ROE of +0.12%. Regarding short-term risk, MDAI is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check PEN's competition here
MDAI vs SWAV Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, MDAI is priced at $2.24, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SWAV's P/E ratio is 78.76. In terms of profitability, MDAI's ROE is +1.79%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, MDAI is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SWAV's competition here
MDAI vs ALGN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, MDAI is priced at $2.24, while ALGN trades at $158.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ALGN's P/E ratio is 26.73. In terms of profitability, MDAI's ROE is +1.79%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, MDAI is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ALGN's competition here
MDAI vs GMED Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, MDAI is priced at $2.24, while GMED trades at $78.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas GMED's P/E ratio is 18.44. In terms of profitability, MDAI's ROE is +1.79%, compared to GMED's ROE of +0.13%. Regarding short-term risk, MDAI is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check GMED's competition here
MDAI vs PODD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PODD has a market cap of 10.6B. Regarding current trading prices, MDAI is priced at $2.24, while PODD trades at $152.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PODD's P/E ratio is 35.71. In terms of profitability, MDAI's ROE is +1.79%, compared to PODD's ROE of +0.21%. Regarding short-term risk, MDAI is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check PODD's competition here
MDAI vs MASI Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, MDAI is priced at $2.24, while MASI trades at $178.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas MASI's P/E ratio is 44.37. In terms of profitability, MDAI's ROE is +1.79%, compared to MASI's ROE of +0.09%. Regarding short-term risk, MDAI is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check MASI's competition here
MDAI vs GKOS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, GKOS has a market cap of 8.3B. Regarding current trading prices, MDAI is priced at $2.24, while GKOS trades at $142.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas GKOS's P/E ratio is -43.07. In terms of profitability, MDAI's ROE is +1.79%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, MDAI is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check GKOS's competition here
MDAI vs BIO Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, MDAI is priced at $2.24, while BIO trades at $281.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BIO's P/E ratio is 46.91. In terms of profitability, MDAI's ROE is +1.79%, compared to BIO's ROE of +0.02%. Regarding short-term risk, MDAI is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BIO's competition here
MDAI vs BIO-B Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, MDAI is priced at $2.24, while BIO-B trades at $267.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BIO-B's P/E ratio is 46.95. In terms of profitability, MDAI's ROE is +1.79%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, MDAI is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BIO-B's competition here
MDAI vs BRKR Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BRKR has a market cap of 6.5B. Regarding current trading prices, MDAI is priced at $2.24, while BRKR trades at $42.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BRKR's P/E ratio is -178.12. In terms of profitability, MDAI's ROE is +1.79%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, MDAI is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BRKR's competition here
MDAI vs NARI Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, MDAI is priced at $2.24, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas NARI's P/E ratio is -59.24. In terms of profitability, MDAI's ROE is +1.79%, compared to NARI's ROE of -0.00%. Regarding short-term risk, MDAI is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check NARI's competition here
MDAI vs LIVN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, MDAI is priced at $2.24, while LIVN trades at $72.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas LIVN's P/E ratio is 36.85. In terms of profitability, MDAI's ROE is +1.79%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, MDAI is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check LIVN's competition here
MDAI vs IRTC Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, MDAI is priced at $2.24, while IRTC trades at $110.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas IRTC's P/E ratio is -129.00. In terms of profitability, MDAI's ROE is +1.79%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, MDAI is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check IRTC's competition here
MDAI vs AXNX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, MDAI is priced at $2.24, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas AXNX's P/E ratio is -709.80. In terms of profitability, MDAI's ROE is +1.79%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, MDAI is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check AXNX's competition here
MDAI vs ITGR Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, MDAI is priced at $2.24, while ITGR trades at $89.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ITGR's P/E ratio is 22.33. In terms of profitability, MDAI's ROE is +1.79%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, MDAI is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ITGR's competition here
MDAI vs TMDX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, MDAI is priced at $2.24, while TMDX trades at $68.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas TMDX's P/E ratio is 15.64. In terms of profitability, MDAI's ROE is +1.79%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, MDAI is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check TMDX's competition here
MDAI vs AXGN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, MDAI is priced at $2.24, while AXGN trades at $41.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas AXGN's P/E ratio is -65.55. In terms of profitability, MDAI's ROE is +1.79%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, MDAI is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check AXGN's competition here
MDAI vs NUVA Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, MDAI is priced at $2.24, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas NUVA's P/E ratio is 75.00. In terms of profitability, MDAI's ROE is +1.79%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, MDAI is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check NUVA's competition here
MDAI vs ESTA Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, MDAI is priced at $2.24, while ESTA trades at $65.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ESTA's P/E ratio is -44.65. In terms of profitability, MDAI's ROE is +1.79%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, MDAI is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ESTA's competition here
MDAI vs UFPT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, MDAI is priced at $2.24, while UFPT trades at $217.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas UFPT's P/E ratio is 24.77. In terms of profitability, MDAI's ROE is +1.79%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, MDAI is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check UFPT's competition here
MDAI vs PRCT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, MDAI is priced at $2.24, while PRCT trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PRCT's P/E ratio is -14.21. In terms of profitability, MDAI's ROE is +1.79%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, MDAI is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check PRCT's competition here
MDAI vs AHCO Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, MDAI is priced at $2.24, while AHCO trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas AHCO's P/E ratio is -18.17. In terms of profitability, MDAI's ROE is +1.79%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, MDAI is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check AHCO's competition here
MDAI vs ENOV Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, MDAI is priced at $2.24, while ENOV trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ENOV's P/E ratio is -1.27. In terms of profitability, MDAI's ROE is +1.79%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, MDAI is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ENOV's competition here
MDAI vs HSKA Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, MDAI is priced at $2.24, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas HSKA's P/E ratio is -62.49. In terms of profitability, MDAI's ROE is +1.79%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, MDAI is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check HSKA's competition here
MDAI vs ATEC Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, MDAI is priced at $2.24, while ATEC trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ATEC's P/E ratio is -9.75. In terms of profitability, MDAI's ROE is +1.79%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, MDAI is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ATEC's competition here
MDAI vs INSP Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, MDAI is priced at $2.24, while INSP trades at $41.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas INSP's P/E ratio is 9.50. In terms of profitability, MDAI's ROE is +1.79%, compared to INSP's ROE of +0.18%. Regarding short-term risk, MDAI is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check INSP's competition here
MDAI vs AVNS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, MDAI is priced at $2.24, while AVNS trades at $24.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas AVNS's P/E ratio is -15.45. In terms of profitability, MDAI's ROE is +1.79%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, MDAI is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check AVNS's competition here
MDAI vs AORT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, MDAI is priced at $2.24, while AORT trades at $23.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas AORT's P/E ratio is 95.04. In terms of profitability, MDAI's ROE is +1.79%, compared to AORT's ROE of +0.03%. Regarding short-term risk, MDAI is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check AORT's competition here
MDAI vs IRMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, MDAI is priced at $2.24, while IRMD trades at $88.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas IRMD's P/E ratio is 48.36. In terms of profitability, MDAI's ROE is +1.79%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, MDAI is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check IRMD's competition here
MDAI vs SILK Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, MDAI is priced at $2.24, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SILK's P/E ratio is -18.96. In terms of profitability, MDAI's ROE is +1.79%, compared to SILK's ROE of -0.35%. Regarding short-term risk, MDAI is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SILK's competition here
MDAI vs CNMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, MDAI is priced at $2.24, while CNMD trades at $36.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CNMD's P/E ratio is 20.67. In terms of profitability, MDAI's ROE is +1.79%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, MDAI is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CNMD's competition here
MDAI vs FNA Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, MDAI is priced at $2.24, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas FNA's P/E ratio is -19.83. In terms of profitability, MDAI's ROE is +1.79%, compared to FNA's ROE of -0.35%. Regarding short-term risk, MDAI is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check FNA's competition here
MDAI vs IART Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, MDAI is priced at $2.24, while IART trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas IART's P/E ratio is -2.18. In terms of profitability, MDAI's ROE is +1.79%, compared to IART's ROE of -0.48%. Regarding short-term risk, MDAI is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check IART's competition here
MDAI vs BFLY Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, MDAI is priced at $2.24, while BFLY trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BFLY's P/E ratio is -12.82. In terms of profitability, MDAI's ROE is +1.79%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, MDAI is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BFLY's competition here
MDAI vs TNDM Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, TNDM has a market cap of 927.2M. Regarding current trading prices, MDAI is priced at $2.24, while TNDM trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas TNDM's P/E ratio is -9.88. In terms of profitability, MDAI's ROE is +1.79%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, MDAI is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check TNDM's competition here
MDAI vs INMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, INMD has a market cap of 893.4M. Regarding current trading prices, MDAI is priced at $2.24, while INMD trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas INMD's P/E ratio is 10.44. In terms of profitability, MDAI's ROE is +1.79%, compared to INMD's ROE of +0.13%. Regarding short-term risk, MDAI is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check INMD's competition here
MDAI vs CSII Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, MDAI is priced at $2.24, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CSII's P/E ratio is -20.83. In terms of profitability, MDAI's ROE is +1.79%, compared to CSII's ROE of -0.14%. Regarding short-term risk, MDAI is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CSII's competition here
MDAI vs SSII Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SSII has a market cap of 796.5M. Regarding current trading prices, MDAI is priced at $2.24, while SSII trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SSII's P/E ratio is -79.60. In terms of profitability, MDAI's ROE is +1.79%, compared to SSII's ROE of -0.23%. Regarding short-term risk, MDAI is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SSII's competition here
MDAI vs CRY Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, MDAI is priced at $2.24, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CRY's P/E ratio is 425.71. In terms of profitability, MDAI's ROE is +1.79%, compared to CRY's ROE of +0.03%. Regarding short-term risk, MDAI is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CRY's competition here
MDAI vs BVS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BVS has a market cap of 720.2M. Regarding current trading prices, MDAI is priced at $2.24, while BVS trades at $10.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BVS's P/E ratio is 25.93. In terms of profitability, MDAI's ROE is +1.79%, compared to BVS's ROE of +0.16%. Regarding short-term risk, MDAI is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BVS's competition here
MDAI vs SIBN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SIBN has a market cap of 654.6M. Regarding current trading prices, MDAI is priced at $2.24, while SIBN trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SIBN's P/E ratio is -37.85. In terms of profitability, MDAI's ROE is +1.79%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, MDAI is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SIBN's competition here
MDAI vs LMRI Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, LMRI has a market cap of 650.7M. Regarding current trading prices, MDAI is priced at $2.24, while LMRI trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas LMRI's P/E ratio is -17.36. In terms of profitability, MDAI's ROE is +1.79%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, MDAI is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check LMRI's competition here
MDAI vs CBLL Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CBLL has a market cap of 629.1M. Regarding current trading prices, MDAI is priced at $2.24, while CBLL trades at $16.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CBLL's P/E ratio is -10.23. In terms of profitability, MDAI's ROE is +1.79%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, MDAI is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CBLL's competition here
MDAI vs SRDX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, MDAI is priced at $2.24, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SRDX's P/E ratio is -34.66. In terms of profitability, MDAI's ROE is +1.79%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, MDAI is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SRDX's competition here
MDAI vs BWAY Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BWAY has a market cap of 583.6M. Regarding current trading prices, MDAI is priced at $2.24, while BWAY trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BWAY's P/E ratio is 82.67. In terms of profitability, MDAI's ROE is +1.79%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, MDAI is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check BWAY's competition here
MDAI vs APEN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, MDAI is priced at $2.24, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas APEN's P/E ratio is -9.43. In terms of profitability, MDAI's ROE is +1.79%, compared to APEN's ROE of -0.85%. Regarding short-term risk, MDAI is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check APEN's competition here
MDAI vs NPCE Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, NPCE has a market cap of 545.2M. Regarding current trading prices, MDAI is priced at $2.24, while NPCE trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas NPCE's P/E ratio is -24.60. In terms of profitability, MDAI's ROE is +1.79%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, MDAI is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check NPCE's competition here
MDAI vs ZIMV Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, MDAI is priced at $2.24, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, MDAI's ROE is +1.79%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, MDAI is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ZIMV's competition here
MDAI vs TCMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, TCMD has a market cap of 533.5M. Regarding current trading prices, MDAI is priced at $2.24, while TCMD trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas TCMD's P/E ratio is 27.18. In terms of profitability, MDAI's ROE is +1.79%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, MDAI is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check TCMD's competition here
MDAI vs OFIX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, OFIX has a market cap of 490.7M. Regarding current trading prices, MDAI is priced at $2.24, while OFIX trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas OFIX's P/E ratio is -8.09. In terms of profitability, MDAI's ROE is +1.79%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, MDAI is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check OFIX's competition here
MDAI vs CERS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CERS has a market cap of 486.9M. Regarding current trading prices, MDAI is priced at $2.24, while CERS trades at $2.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CERS's P/E ratio is -48.60. In terms of profitability, MDAI's ROE is +1.79%, compared to CERS's ROE of -0.15%. Regarding short-term risk, MDAI is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CERS's competition here
MDAI vs KIDS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, KIDS has a market cap of 465.9M. Regarding current trading prices, MDAI is priced at $2.24, while KIDS trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas KIDS's P/E ratio is -10.80. In terms of profitability, MDAI's ROE is +1.79%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, MDAI is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check KIDS's competition here
MDAI vs CTKB Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CTKB has a market cap of 458.5M. Regarding current trading prices, MDAI is priced at $2.24, while CTKB trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CTKB's P/E ratio is -6.12. In terms of profitability, MDAI's ROE is +1.79%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, MDAI is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CTKB's competition here
MDAI vs VREX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, VREX has a market cap of 408.4M. Regarding current trading prices, MDAI is priced at $2.24, while VREX trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas VREX's P/E ratio is -4.85. In terms of profitability, MDAI's ROE is +1.79%, compared to VREX's ROE of -0.18%. Regarding short-term risk, MDAI is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check VREX's competition here
MDAI vs LAB Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, LAB has a market cap of 386.1M. Regarding current trading prices, MDAI is priced at $2.24, while LAB trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas LAB's P/E ratio is -7.61. In terms of profitability, MDAI's ROE is +1.79%, compared to LAB's ROE of -0.21%. Regarding short-term risk, MDAI is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check LAB's competition here
MDAI vs DCTH Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, DCTH has a market cap of 382.8M. Regarding current trading prices, MDAI is priced at $2.24, while DCTH trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas DCTH's P/E ratio is 1109.00. In terms of profitability, MDAI's ROE is +1.79%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, MDAI is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check DCTH's competition here
MDAI vs VMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, VMD has a market cap of 369.6M. Regarding current trading prices, MDAI is priced at $2.24, while VMD trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas VMD's P/E ratio is 26.05. In terms of profitability, MDAI's ROE is +1.79%, compared to VMD's ROE of +0.11%. Regarding short-term risk, MDAI is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check VMD's competition here
MDAI vs PACB Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, MDAI is priced at $2.24, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PACB's P/E ratio is -2.80. In terms of profitability, MDAI's ROE is +1.79%, compared to PACB's ROE of -4.88%. Regarding short-term risk, MDAI is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check PACB's competition here
MDAI vs CLPT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CLPT has a market cap of 333.8M. Regarding current trading prices, MDAI is priced at $2.24, while CLPT trades at $11.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CLPT's P/E ratio is -11.13. In terms of profitability, MDAI's ROE is +1.79%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, MDAI is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CLPT's competition here
MDAI vs ELMD Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ELMD has a market cap of 316.7M. Regarding current trading prices, MDAI is priced at $2.24, while ELMD trades at $38.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ELMD's P/E ratio is 32.69. In terms of profitability, MDAI's ROE is +1.79%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, MDAI is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ELMD's competition here
MDAI vs SMLR Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, MDAI is priced at $2.24, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SMLR's P/E ratio is 3.92. In terms of profitability, MDAI's ROE is +1.79%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, MDAI is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SMLR's competition here
MDAI vs CATX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CATX has a market cap of 291.2M. Regarding current trading prices, MDAI is priced at $2.24, while CATX trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CATX's P/E ratio is -2.67. In terms of profitability, MDAI's ROE is +1.79%, compared to CATX's ROE of -0.42%. Regarding short-term risk, MDAI is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CATX's competition here
MDAI vs AVR Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, AVR has a market cap of 278.5M. Regarding current trading prices, MDAI is priced at $2.24, while AVR trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas AVR's P/E ratio is -3.41. In terms of profitability, MDAI's ROE is +1.79%, compared to AVR's ROE of -1.24%. Regarding short-term risk, MDAI is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check AVR's competition here
MDAI vs PMI Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PMI has a market cap of 266.8M. Regarding current trading prices, MDAI is priced at $2.24, while PMI trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PMI's P/E ratio is -0.23. In terms of profitability, MDAI's ROE is +1.79%, compared to PMI's ROE of +4.99%. Regarding short-term risk, MDAI is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for MDAI.Check PMI's competition here
MDAI vs SGHT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SGHT has a market cap of 264.4M. Regarding current trading prices, MDAI is priced at $2.24, while SGHT trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SGHT's P/E ratio is -6.94. In terms of profitability, MDAI's ROE is +1.79%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, MDAI is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SGHT's competition here
MDAI vs MASS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, MASS has a market cap of 251.1M. Regarding current trading prices, MDAI is priced at $2.24, while MASS trades at $6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas MASS's P/E ratio is -6.85. In terms of profitability, MDAI's ROE is +1.79%, compared to MASS's ROE of -0.26%. Regarding short-term risk, MDAI is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check MASS's competition here
MDAI vs RXST Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, RXST has a market cap of 248.4M. Regarding current trading prices, MDAI is priced at $2.24, while RXST trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas RXST's P/E ratio is -5.31. In terms of profitability, MDAI's ROE is +1.79%, compared to RXST's ROE of -0.17%. Regarding short-term risk, MDAI is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check RXST's competition here
MDAI vs MGRM Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, MDAI is priced at $2.24, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas MGRM's P/E ratio is -11.11. In terms of profitability, MDAI's ROE is +1.79%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, MDAI is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check MGRM's competition here
MDAI vs SENS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SENS has a market cap of 232.4M. Regarding current trading prices, MDAI is priced at $2.24, while SENS trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SENS's P/E ratio is -2.82. In terms of profitability, MDAI's ROE is +1.79%, compared to SENS's ROE of -1.30%. Regarding short-term risk, MDAI is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SENS's competition here
MDAI vs NVRO Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, MDAI is priced at $2.24, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas NVRO's P/E ratio is -1.91. In terms of profitability, MDAI's ROE is +1.79%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, MDAI is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check NVRO's competition here
MDAI vs EYES Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, MDAI is priced at $2.24, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas EYES's P/E ratio is N/A. In terms of profitability, MDAI's ROE is +1.79%, compared to EYES's ROE of -2.64%. Regarding short-term risk, MDAI is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check EYES's competition here
MDAI vs PROF Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, PROF has a market cap of 208.5M. Regarding current trading prices, MDAI is priced at $2.24, while PROF trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas PROF's P/E ratio is -5.56. In terms of profitability, MDAI's ROE is +1.79%, compared to PROF's ROE of -0.71%. Regarding short-term risk, MDAI is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check PROF's competition here
MDAI vs ANIK Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, ANIK has a market cap of 198.9M. Regarding current trading prices, MDAI is priced at $2.24, while ANIK trades at $14.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas ANIK's P/E ratio is -18.92. In terms of profitability, MDAI's ROE is +1.79%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, MDAI is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check ANIK's competition here
MDAI vs BSGM Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, MDAI is priced at $2.24, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas BSGM's P/E ratio is -5.81. In terms of profitability, MDAI's ROE is +1.79%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, MDAI is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for MDAI.Check BSGM's competition here
MDAI vs MDGS Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, MDAI is priced at $2.24, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas MDGS's P/E ratio is -0.27. In terms of profitability, MDAI's ROE is +1.79%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, MDAI is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for MDAI.Check MDGS's competition here
MDAI vs TMCI Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, TMCI has a market cap of 178.4M. Regarding current trading prices, MDAI is priced at $2.24, while TMCI trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas TMCI's P/E ratio is -2.86. In terms of profitability, MDAI's ROE is +1.79%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, MDAI is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check TMCI's competition here
MDAI vs INGN Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, INGN has a market cap of 170.6M. Regarding current trading prices, MDAI is priced at $2.24, while INGN trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas INGN's P/E ratio is -6.92. In terms of profitability, MDAI's ROE is +1.79%, compared to INGN's ROE of -0.13%. Regarding short-term risk, MDAI is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check INGN's competition here
MDAI vs EDAP Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, EDAP has a market cap of 167.9M. Regarding current trading prices, MDAI is priced at $2.24, while EDAP trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas EDAP's P/E ratio is -5.46. In terms of profitability, MDAI's ROE is +1.79%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, MDAI is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check EDAP's competition here
MDAI vs QIPT Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, MDAI is priced at $2.24, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas QIPT's P/E ratio is -15.87. In terms of profitability, MDAI's ROE is +1.79%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, MDAI is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check QIPT's competition here
MDAI vs APYX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, APYX has a market cap of 162.1M. Regarding current trading prices, MDAI is priced at $2.24, while APYX trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas APYX's P/E ratio is -17.59. In terms of profitability, MDAI's ROE is +1.79%, compared to APYX's ROE of -0.91%. Regarding short-term risk, MDAI is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check APYX's competition here
MDAI vs CVRX Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, CVRX has a market cap of 157M. Regarding current trading prices, MDAI is priced at $2.24, while CVRX trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas CVRX's P/E ratio is -2.96. In terms of profitability, MDAI's ROE is +1.79%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, MDAI is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check CVRX's competition here
MDAI vs QTI Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, QTI has a market cap of 149M. Regarding current trading prices, MDAI is priced at $2.24, while QTI trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas QTI's P/E ratio is -2.73. In terms of profitability, MDAI's ROE is +1.79%, compared to QTI's ROE of -63.30%. Regarding short-term risk, MDAI is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check QTI's competition here
MDAI vs SNWV Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, SNWV has a market cap of 145M. Regarding current trading prices, MDAI is priced at $2.24, while SNWV trades at $16.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas SNWV's P/E ratio is 17.56. In terms of profitability, MDAI's ROE is +1.79%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, MDAI is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check SNWV's competition here
MDAI vs HYPR Comparison May 2026
MDAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDAI stands at 71.3M. In comparison, HYPR has a market cap of 121M. Regarding current trading prices, MDAI is priced at $2.24, while HYPR trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDAI currently has a P/E ratio of -4.23, whereas HYPR's P/E ratio is -3.62. In terms of profitability, MDAI's ROE is +1.79%, compared to HYPR's ROE of -1.01%. Regarding short-term risk, MDAI is more volatile compared to HYPR. This indicates potentially higher risk in terms of short-term price fluctuations for MDAI.Check HYPR's competition here